AI adapts artificial DNA for future drug development

AI adapts artificial DNA for future drug development

image: AI adapts artificial DNA
see After

Credit: Credit: Yen Strandqvist

With the help of an AI, researchers at Chalmers University of Technology in Sweden have succeeded in designing synthetic DNA that controls the production of proteins in cells. The technology can contribute to the development and production of vaccines, drugs for serious illnesses, as well as alternative dietary proteins much faster and at significantly lower costs than today.

The way our genes are expressed is a fundamental process for the functionality of cells in all living organisms. Simply put, the genetic code of DNA is transcribed into a messenger RNA (mRNA) molecule, which tells the cell factory what protein to produce and in what quantity.

Researchers have put a lot of effort into trying to control gene expression, as it can, among other things, contribute to the development of protein-based drugs. A recent example is the mRNA vaccine against Covid-19, which instructed cells in the body to produce the same protein found on the surface of the coronavirus. The body’s immune system could then learn to form antibodies against the virus. Similarly, it is possible to teach the body’s immune system to defeat cancer cells or other complex diseases if one understands the genetic code behind the production of specific proteins.

Most of today’s new drugs are protein-based, but production techniques are both expensive and slow because it is difficult to control DNA expression. Last year, a research group at Chalmers, led by Aleksej Zelezniak, associate professor of systems biology, took an important step in understanding and controlling how much of a protein is made from a certain sequence. of DNA.

“First it was about being able to completely ‘read’ the instructions of the DNA molecule. Now we have succeeded in designing our own DNA which contains the exact instructions to control the amount of a specific protein”, explains Aleksej Zelezniak about the research group’s latest major study. breakthrough.

Tailor-made DNA molecules

The principle of the new method is similar to the case where an AI generates faces that look like real people. By learning what a wide selection of faces look like, the AI ​​can then create completely new but natural-looking faces. It is then easy to modify a face by saying for example that it should look older, or have a different hairstyle. On the other hand, programming a believable face from scratch, without the use of AI, would have been much more difficult and time-consuming. Likewise, the researchers’ AI learned the structure and regulatory code of DNA. The AI ​​then designs synthetic DNA, where it is easy to modify its regulatory information in the desired direction of gene expression. Simply put, the AI ​​is told how much of a gene it wants and then “prints” the appropriate DNA sequence.

“DNA is an incredibly long and complex molecule. It is therefore experimentally extremely difficult to make changes to it by reading and modifying it iteratively, then reading and modifying it again. That way, it takes years of research to find something that works. Instead, it’s far more efficient to let an AI learn the principles of DNA navigation. What would otherwise take years is now reduced to weeks or days,” says first author Jan Zrimec, research associate at the National Institute of Biology in Slovenia and a former postdoc in Aleksej Zelezniak’s group.

The researchers developed their method in the yeast Saccharomyces cerevisiae, whose cells resemble mammalian cells. The next step is to use human cells. The researchers hope their progress will have an impact on the development of new and existing drugs.

“Protein-based drugs for complex diseases or sustainable dietary protein alternatives can take many years and can be extremely expensive to develop. makes it economically unviable. With our technology, it is possible to develop and manufacture proteins much more efficiently so that they can be commercialized,” says Aleksej Zelezniak.

The authors of the study are Jan Zrimec, Xiaozhi Fu, Azam Sheikh Muhammad, Christos Skrekas, Vykintas Jauniskis, Nora K. Speicher, Christoph S. Börlin, Vilhelm Verendel, Morteza Haghir Chehreghani, Devdatt Dubhashi, Verena Siewers, Florian David, Jens Nielsen and Aleksej Zelezniak.

The researcher is active at Chalmers University of Technology, Sverige; National Institute of Biology, Slovenia; Biomatter Designs, Lithuania; Institute of Biotechnology, Lithuania; BioInnovation Institute, Denmark; King’s College London, UK.

For more information please contact: Alexei ZeleznyakAssociate Professor, Department of Biology and Bioengineering, Chalmers University of Technology, +46 31 772 81 71, aleksej.zelezniak@chalmers.se​

Read the full study: Controlling gene expression through in-depth generative design of regulatory DNA

Legend: Aleksej Zelezniak, Associate Professor, Department of Biology and Biological Engineering, Chalmers University of Technology

Illustration credit: Yen Strandqvist, Chalmers


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

#adapts #artificial #DNA #future #drug #development

Leave a Comment

Your email address will not be published. Required fields are marked *